EYEN Eyenovia Inc

Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

Company to host an investor conference call and webcast at 4:30pm EDT

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the Company will release financial results for the second quarter ended June 30, 2023 on Thursday, August 10, 2023, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. EDT to review the financial and operating results.

Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and referencing conference ID 13739696.

To access the Call me™ feature, which avoids having to wait for an operator, click .

A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at .

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide + phenylephrine ophthalmic spray) for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression (partnered with Bausch+Lomb). For more information, visit .

The Eyenovia Corporate Information slide deck may be found at .

Eyenovia Contact:

Eyenovia, Inc.

John Gandolfo

Chief Financial Officer

Eyenovia Investor Contact:

Eric Ribner

LifeSci Advisors, LLC



(646) 751-4363

Eyenovia Media Contact:

Eyenovia, Inc.

Norbert Lowe

Vice President, Commercial Operations





EN
07/08/2023

Underlying

EYENEyenovia Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eyenovia Inc

 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion De...

Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. Name change reflects company’s leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to commence trading on Nasdaq under the symbol “HYPD” effective July 3rd Also announces official launch of the Kinetiq x Hyperion validator LAGUNA HILLS, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, th...

July 2, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparat...

Eyenovia Adds $10 Million in HYPE to its Treasury Holdings in Preparation for Strategic Onchain Engagement Increases total holdings to 1,306,452 HYPE LAGUNA HILLS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it has acquired an additional 265,872 HYPE tokens, expanding its total holdings to 1,306,452 HYPE purchased at an average price of $34.83 pe...

June 30, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Co-Branded Validator with Kinetiq 

Eyenovia Announces Co-Branded Validator with Kinetiq  Kinetiq x Hyperion provides a premier liquid staking solution for institutional HYPE holders LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol built natively for the Hyperliquid ecosystem.  The validator mar...

June 25, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Closing of $50 Million Private Placement, Successfu...

Eyenovia Announces Closing of $50 Million Private Placement, Successful Accumulation of More Than One Million HYPE Tokens, and Update on its Optejet Development Program The significant HYPE token position, acquired at an average price of approximately $34 per token, makes Eyenovia the first Nasdaq listed company to run a validator on Hyperliquid FDA registration of the Optejet User Filled Device (UFD) on track for September 2025; meaningful partnering discussions ongoing LAGUNA HILLS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Com...

June 23, 2025 1 EN
 PRESS RELEASE
Free
EYEN EYENOVIA INC

Eyenovia Announces Appointment of a Strategic Advisor for Digital Asse...

Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group EYEN to bring on major Hyperliquid Thought Leader to support HYPE Treasury Strategy LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capita...

June 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch